Sun Pharmaceutical Industries has struck its largest global deal to acquire US-based Organon for $11.75 billion. This deal expands Sun Pharma’s footprint to 150 markets. Will it pay off?
In a single stroke, the deal takes Sun Pharma from being India’s largest drugmaker to a top-tier global pharmaceutical company doubling its annual revenue to $12 billion, increasing its presence to 150 countries, and giving it a 24,000-strong commercial sales force operating on the same field as Pfizer and AstraZeneca.
Whether it cements Shanghvi’s legacy as the architect of India’s first truly global pharma major, or whether, after four decades of disciplined wins, it finally tests the limits of his manual, will mould what comes next not just for Sun Pharma—where a new generation is ready to take on more—but also for the Indian pharmaceutical industry.
“I’m happy, excited, also a little bit anxious. It is a large transaction that we are entering into,” Shanghvi said at a press conference announcing the deal.
A man who has spent over four decades being almost pathologically cautious is now writing the largest cheque of his life, a contrast that traces back to a wholesale medicine shop in the dust and din of Kolkata’s bustling Dawa Bazar. It is also the first time he is stepping into businesses and geographies where Sun has limited prior operating experience.
With Organon, Shanghvi is taking Sun into a different league, competing not just with the world’s largest generics manufacturers, but increasingly with multinational pharmaceutical companies that control innovation, brands and commercial reach.
“As a company, we always want to compete with players bigger than us,” Shanghvi had told Business Today in an earlier interaction. “In each of the businesses we are present in, like generics, we have become a very big player because we continue to grow.”
For a businessman who began with five psychiatry products and one salesman, the scale of the leap has been extraordinary.
Shanghvi’s father, Shantilal, ran a small medicine distributorship business in Kolkata, where the young Dilip, by his own account, would pore over drug labels and wonder how the molecules inside the bottles were made. For most boys growing up in such a setting, the predictable arc would have been to inherit the shop, marry well, and settle into the comfortable rhythms of the city’s wholesale trade. Shanghvi chose a different path.
In the summer of 1983, the 28-year-old borrowed Rs 10,000 from his father, packed up for Vapi in Gujarat, and set up a small drug manufacturing unit with five psychiatry products. He named the company Sun Pharmaceutical Industries. “The sun is the perennial source of all energy ,” he says.
Shanghvi is known for a personal, measured and understated style. He dresses simply, with little to suggest the scale of the business he runs. He avoids corporate social circuits and keeps a tightly controlled routine, but is fond of idlis from a South Indian joint in Mumbai that friends occasionally drop off at his home. His biography, The Reluctant Billionaire, is aptly titled. And yet the reluctance has always been selective. On the big calls, like the acquisition of Israel-based Taro in 2010, Ranbaxy in 2015, and now Organon, Shanghvi has shown a willingness to move single-mindedly in ways that stand in stark contrast to his otherwise cautious nature.
When Sun Pharma went through its toughest phase between 2014 and 2018—coinciding with the acquisition of the embattled Ranbaxy, pricing collapse in the US generics market, warning letters from the US FDA, and a 70% crash in profits in FY18—Shanghvi did what he has always done: he fought, in his low-profile but unyielding manner.
For instance, Sun lost nearly a billion dollars in revenue as pricing pressure intensified in the US generics market amid customer consolidation and increased competition. It responded by building newer profit streams through specialty medicines, increasing its presence in emerging markets and expanding its portfolio in India.
The net profit fell from Rs 4,777 crore in FY17 to Rs 3,301 crore in FY18. And revenue from Rs 27,518 crore to Rs 26,066 crore. In FY25, the net profit was around Rs 11,000 crore, on a revenue of over Rs 55,000 crore, with specialty medicines continuing to drive growth.
The Organon bet draws directly from the operating philosophy Shanghvi has built over the years—disciplined scaling, incremental improvement and long-term positioning rather than short-term market applause.
“Each of our businesses should focus on improving its performance last year,” Shanghvi had told BT in an earlier interaction.
Sun’s push into innovative medicines began more than a decade ago as the company sought to move beyond pure generics and create additional growth engines. “We have demonstrated our ability to find a way to grow the business,” Shanghvi said in the investor call after the accouncement of the recent deal.
Organon may be the biggest expression yet of that philosophy. For Shanghvi, the acquisition is not just a scale play but continuation of a strategy he has been building for over a decade. The transaction is structured with the financial discipline that has become a Sun signature.
For FY25, Sun Pharma reported gross sales of Rs 52,041 crore (around $6 billion). With the proposed Organon acquisition, combined revenue is expected to cross $12 billion, implying an increase of more than 100% over Sun Pharma’s current size. Organon operates in around 140 countries, while the combined Sun Pharma-Organon company will have presence in about 150 countries.
The acquisition will be funded through internal cash accruals and committed bank financing from lenders including Citigroup, JPMorgan and MUFG. The transaction will be executed through the merger of Organon with a Sun Pharma subsidiary, with Organon continuing as the surviving entity under Sun Pharma ownership. The eventual operating structure and integration roadmap, however, will evolve over time as the combined business is integrated.
Organon’s existing $8.6 billion debt, combined with Sun’s acquisition financing, will leave the company at roughly 2.3 times net debt to Ebitda in its first full year.
Shanghvi said Organon’s size and profitability were comparable to Sun’s, but the valuation gap reflected the different growth trajectories of the two companies. While Sun has been expanding consistently, Organon’s businesses have been largely stagnant, creating what he described as an opportunity to revive growth. “We know that for us to create value, the key driver is to find a way to grow this business much better than what it has been able to do,” he said.
Shanghvi acknowledged investor concerns around the scale of debt required for the acquisition. Sun has historically operated as a low-debt or a cash-positive company, but the management believes leverage is justified if it helps fundamentally alter the company’s direction. “As a company, we ourselves are debt-averse. However, we are not risk-averse…personally, I am not comfortable with debt. I would try and find a way to deliver the company so that we are able to minimise or eliminate the debt.”
However, he added that the leverage remained manageable in the context of the combined earnings and cash generation, and that Sun would remain focused on repaying the debt as early as possible. “Even the debt we got as a result of the Ranbaxy acquisition, we found a way to repay in the shortest possible time.”
The timing reflects two structural shifts in the global pharmaceutical industry. The first is the imminent biosimilar boom, with $320-330 billion worth of biologic products expected to lose patent protection between now and 2035, opening up a $60-70 billion opportunity.
The second is the consolidation of global pharmaceutical distribution. What Sun lacked was a large international commercial presence. Organon, in one transaction, supplies it.
Shanghvi said the acquisition dramatically accelerates Sun’s ability to commercialise products globally and build relationships across markets that would otherwise have taken years to establish.“For Sun, on its own, it would have taken much longer to reach where we can potentially reach post the Organon acquisition.”
“The acquisition would provide scale across innovative medicines, biosimilars and established brands, while also strengthening Sun’s presence in China and women’s health,” say HDFC Securities analysts Mehul Sheth and Divyaxa Agnihotri. “However, reviving growth in Organon’s established brands and managing integration would remain key challenges,” they say.
The transaction also marks one of the boldest attempts by an Indian pharmaceutical company to acquire a global branded healthcare business at scale.
The other key players which led the deal are Kirti Ganorkar, Managing Director, and Jayashree Satagopan, Chief Financial Officer, Sun Pharma. Ganorkar, who was closely involved in the Ranbaxy integration and now leads this one, framed the Organon transaction as an expansion of Sun’s innovative business.
The deal also resolves a long-standing limitation in Sun’s specialty business. Ilumya, the company’s flagship dermatology drug, has been launched in only 35 countries, partly because Sun had to depend on out-licensed commercial partners in markets where it lacked its own sales force.
“Organon is giving the company a platform to commercialise its own innovative products across multiple markets,” Ganorkar tells BT.
The acquisition also adds a meaningful China presence. Organon generates over $800 million from China, roughly 13% of its business, primarily through established brands in cardiovascular, respiratory and fertility segments.
Organon’s portfolio is heavily weighted towards mature established brands, many of which face slower growth and pricing pressure across markets. Sun’s independent presence in China is negligible at present.
Source : Businesstoday
